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Advances in high-throughput genomic-scanning have expanded the repertory of genetic
variations in DNA sequences encoding ErbB tyrosine kinase receptors in humans,
including single nucleotide polymorphisms (SNPs), polymorphic repetitive elements,
microsatellite variations, small-scale insertions and deletions. The ErbB family members:
EGFR, ErbB2, ErbB3, and ErbB4 receptors are established as drivers of many aspects of
tumor initiation and progression to metastasis. This knowledge has provided rationales
for the development of an arsenal of anti-ErbB therapeutics, ranging from small
molecule kinase inhibitors to monoclonal antibodies. Anti-ErbB agents are becoming the
cornerstone therapeutics for the management of cancers that overexpress hyperactive
variants of ErbB receptors, in particular ErbB2-positive breast cancer and non-small
cell lung carcinomas. However, their clinical benefit has been limited to a subset of
patients due to a wide heterogeneity in drug response despite the expression of the
ErbB targets, attributed to intrinsic (primary) and to acquired (secondary) resistance.
Somatic mutations in ErbB tyrosine kinase domains have been extensively investigated
in preclinical and clinical setting as determinants for either high sensitivity or resistance
to anti-ErbB therapeutics. In contrast, only scant information is available on the impact of
SNPs, which are widespread in genes encoding ErbB receptors, on receptor structure
and activity, and their predictive values for drug susceptibility. This review aims to
briefly update polymorphic variations in genes encoding ErbB receptors based on recent
advances in deep sequencing technologies, and to address challenging issues for a better
understanding of the functional impact of single versus combined SNPs in ErbB genes
to receptor topology, receptor-drug interaction, and drug susceptibility. The potential of
exploiting SNPs in the era of stratified targeted therapeutics is discussed.
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AN OVERVIEW OF ErbB RECEPTOR SIGNALING
Since the pioneering discovery of epidermal growth factor recep-
tor (EGFR), the founding member of the ErbB protein tyrosine
kinase family by Stanley Cohen, a contribution recognized as 1986
Nobel Prize of Medicine, a remarkable progress has been made
in the characterization of this receptor family, which in addi-
tion to EGFR/ErbB1/HER1, includes ErbB2/HER2, ErbB3/HER3,
and ErbB4/HER4 (Chinkers and Cohen, 1981). These homolo-
gous receptors are type 1 transmembrane proteins that share a
common structure with a large glycosylated ligand binding extra-
cellular region composed of domains I-IV, a single hydropho-
bic transmembrane region, a cytoplasmic domain with tyrosine
kinase activity, and a C-terminal tail containing multiple phos-
phorylation sites required for propagation of downstream signal-
ing (Figure 1). The strongest homology among ErbB receptors is
seen in the kinase domain (59–82%) followed by the extracellular
domain (36–48%) and the C-terminal tail (24–33%) (Gschwind
et al., 2004). There are unique features characterizing two mem-
bers of this family: the first is the lack of kinase activity in ErbB3
receptor, a deficiency proposed to be due to substitution of a
conserved aspartate (Asp/D) residue to an asparagine (Asn/N)
in the kinase domain. Therefore, ErbB3 activation relies on het-
erodimerization with the other members of the family (Citri
et al., 2003). The second is the orphan ErbB2, which lacks a
specific ligand. Structural studies have revealed that the ligand-
binding site of ErbB2 is constitutionally in activate conformation,
and thus prone for heterodimerization and transphosphoryla-
tion through interactions with the other ligand-activated ErbB
receptors (Garrett et al., 2003).
ErbB receptors have a propensity to be activated by a wide
range of ligands, which include epidermal growth factor (EGF),
transforming growth factor α (TGFα), heparin-binding epider-
mal growth factor, amphiregulin, betacellulin, epiregulin, and
neuregulins. These ligands induce a broad array of ErbB recep-
tor homo- and heterodimerization culminating into a diverse cell
transduction signaling of utmost importance to both physiologi-
cal and pathological contexts, including embryonic development
(Gassmann et al., 1995; O-Charoenrat et al., 2002; Stein and
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FIGURE 1 | Representation of epidermal growth factor receptors family
(EGFR/ErbB1, ErbB2, ErbB3, and ErbB4) showing the distribution of
the main SNPs mutations in the extracellular domain, transmembrane
region, and intracellular domain comprising the tyrosine kinase and
autophosphorylation sites. Boxes represent functional domains: I,
extracellular domain sub-region I; II, extracellular domain sub-region II; III,
extracellular domain sub-region III; IV, extracellular domain sub-region IV.
(Prickett et al., 2009; Yarden and Pines, 2012; Li et al., 2014)
Staros, 2006; Birchmeier, 2009). The general mode of activation
of ErbB receptors involves changes in allosteric conformations
due to intermolecular mechanisms triggered by ligand activation
and/or activating mutations (Monsey et al., 2010; Lemmon et al.,
2014). Both homo- and heterodimerization with partners involve
primarily the kinase domain and C-lobe surface structures of
ErbB receptors (Burgess et al., 2003; Zhang et al., 2006; Monsey
et al., 2010). For example, the ligand binds between domains I
and III (extracellular region) of the EGFR and ErbB3 receptors
to induce conformational change and subsequent dimerization
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and kinase activation. A widely accepted model of activation
stipulates that dimerization occurs via an asymmetric mode
where a C-lobe of an acceptor monomer and the N-lobe of a
donor monomer in the intracellular juxtamembrane region inter-
acts. Mutations in the asymmetric dimer interface can abolish
kinase activation (Zhang et al., 2006, 2007; Red Brewer et al.,
2009). In this mode of activation, C-lobe surface amino acids,
the extracellular domain, the transmembrane domain, and the
intracellular juxtamembrane region all can influence receptor
dimerization and the intensity of activation (Burgess et al., 2003;
Thiel and Carpenter, 2007; Lemmon, 2009). This suggests that
subtle molecular changes in the receptor structure due to sin-
gle nucleotide polymorphisms (SNPs) can impact on ErbB kinase
activity as well as ErbB receptor interaction with ligands, down-
stream partners, or with inhibitors including anti-ErbB mono-
clonal antibodies (Shigematsu et al., 2005; Fan et al., 2008).
ErbB RECEPTORS: A SUCCESS STORY IN DISCOVERY OF
THERAPEUTIC TARGETS AND LIMITATIONS
In general, ErbB receptors are expressed at low levels on the sur-
face of normal adult epithelial cells (O-Charoenrat et al., 2002).
Extensive preclinical studies in cell lines and transgenic mouse
models established the contribution of dysfunctional ErbB signal-
ing, due to overexpression and hyperactivation, to carcinogenesis
(Bargmann et al., 1986; Bouchard et al., 1989). In cancer cells,
aberrant activation due to gene overexpression and/or amplifi-
cation and (less commonly) mutation scan promote enhanced
cell proliferation, resistance to apoptosis, and higher cell inva-
siveness. In several cancer types, in particular breast, ovarian,
gastric, and non-small cell carcinoma of the lung, amplification
and/or overexpression of specific members of the ErbB receptor
family have been associated with poor clinical prognosis, includ-
ing high incidence of metastasis and recurrence. In breast cancer,
molecular profiling studies have enabled identification of ErbB2-
positivebreast cancer molecular subtype, which represents up to
30% of breast cancers. In this subtype, the amplified and/or
overexpressed ErbB2 induces enrichment of several downstream
ErbB2-regulated genes (Slamon et al., 1989; Cancer Genome Atlas
Network, 2012).
The remarkable progress in the understanding the biology of
ErbB signaling in cancer has led to the discovery of several tar-
geted agents against ErbB members, including small molecule
tyrosine kinase inhibitors (TKIs) and monoclonal antibodies
(MAbs).At present, small molecule inhibitors under clinical trials
or approved by the US Food and Drug Administration (FDA) are
either reversible or irreversible inhibitors that bind to the ATP-
binding site in the kinase domain of ErbB receptors (Table 1).
In addition to TKIs, several MAbs that target either EGFR (e.g.,
cetuximab), ErbB2 (trastuzumab), or ErbB2 dimerization (per-
tuzumab),are becoming major therapeutics, in particular for the
ErbB2-positive breast cancer subtype where combination of anti-
ErbB2, e.g., trastuzumab with conventional chemotherapy, has
drastically changed the patients’ prognosis and outcome (Piccart-
Gebhart et al., 2005; Romond et al., 2005). As well, combination
of MAbs with TKIs, e.g., trastuzumab plus anti-EGFR/anti-ErbB2
such as lapatinib or pertuzumab, revealed of clinical benefit for
recurrent cancers following trastuzumab treatment for instance
(Geyer et al., 2006; Joensuu et al., 2006). More recently, a double-
blind placebo-controlled international multicentre clinical trial
(CLEOPATRA)designed to evaluate the efficacy and safety of
pertuzumab+trastuzumab+docetaxel (pertuzumab arm) versus
placebo+trastuzumab+docetaxel (control arm) showed a sur-
vival improvement in the pertuzumab arm and also demon-
strated that ErbB2 marker is suited for patient selection for the
pertuzumab-based regimen in ErbB2-positive metastatic breast
cancer or locally recurrent unresectable tumor (Baselga et al.,
2014; Fleeman et al., 2015).
Despite of these successes, there remain major obstacles in
achieving sustained response or cure with anti-ErbB inhibitors.
The first obstacle refers to de novo or intrinsic resistance seen in
patients expressing the ErbB targets yet failing to respond to anti-
ErbB. This form of resistance is estimated to occur in up to ∼20
and ∼70% of ErbB2-positive patients with early and metastatic
breast cancer treated with trastuzumabmonotherapy, respectively
(Harris et al., 2007; Wolff et al., 2007). The second type of resis-
tance is the acquired form attributed to drug selection and can be
seen in over 50% of patients who initially respond to anti-ErbB
therapeutics but later become refractory to these drugs (Harris
et al., 2007; Wolff et al., 2007).
Studies in preclinical models revealed intrinsic and acquired
resistance to anti-ErbB therapeutics to involve multifactorial
mechanisms both tumor- and host-related (Rexer and Arteaga,
2012). Briefly, mechanisms of primary drug resistance include
emergence of pre-existing tumor cell subpopulations with (i)
specific mutations in ErbB genes affecting the drug-target inter-
action; (ii) alternate splicing of ErbB gene leading to truncated
isoforms of the receptors not recognized by the inhibitor, e.g.,
trastuzumab resistance in breast cancer has been associated with
the expression of a truncated p95-ErbB2 receptor isoform that
lacks trastuzumab antibody binding site; (iii) decreased MAb-
induced cell-mediated cytotoxicity in ErbB2-positive cells such as
due to an alteration in the binding of immune cells to Fc region of
the MAb; and (iv) failure of MAb such as trastuzumab to induce
ErbB2 receptor shedding, internalization, and/or degradation by
ubiquitination (Rexer and Arteaga, 2012).
In contrast to intrinsic resistance, a broader range of mecha-
nisms induced by drug pressure can mediate acquired resistance.
These include secondary mutations that affect drug-ErbB target
interaction (the most common are mutations in the TK domain),
activation of compensatory signaling pathways able to bypass
signaling blockade by the ErbB inhibitors, inefficient cellular
transport/uptake of the drug, enhanced drug inactivation such as
by phase II enzymes, up-regulation of survival signals, and altered
drug pharmacokinetics and pharmacodistribution in the host.
Targeting some of these mechanisms has provided alternative
approaches to overcome resistance to anti-ErbB, e.g., combina-
tion of MAb such as trastuzumab with lapatinib or pertuzumab,
the use of ado-trastuzumabemtansine (T-DM1), or combinations
of trastuzumab with heat shock protein-90 (HSP90) inhibitors,
PI3K inhibitors, and immune checkpoint modulators in combi-
nation with trastuzumab (Amiri-Kordestani et al., 2014).
In contrast to cancer-associated somatic mutations, single
nucleotide polymorphisms (SNPs) are widespread in ErbB genes.
In general, SNPs represent the most common genetic variations
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that occur in over 1.5% of healthy human population. In con-
trast somatic mutations are acquired genetic changes present in
only a subset of cells. While most SNPs are silent with no appar-
ent impact on physiological functions, some SNPs may impact on
individual’s susceptibility to anti-ErbB target therapeutics. The
following chapters review the biological impact and predictive
value of SNPs in ErbB genes.
POTENTIAL IMPACT OF SINGLE NUCLEOTIDE
POLYMORPHISMS IN ErbB GENES ON RECEPTOR ACTIVITY,
DRUG-RECEPTOR INTERACTION AND DRUG EFFICACY
SNPs are genetic variations that occur at a single position in a
DNA sequence with fairly high frequency in the general popula-
tion. SNPs are widespread in genes encoding all the 4 members
of ErbB receptor family. Polymorphic point mutations could lead
to variations in the amino acid sequence, however, SNPs can
also occur in noncoding regions of DNA. In addition, mount-
ing evidence support that genetic polymorphisms can also occur
in microRNA-encoding sequences and this can contribute to
phenotypic differences seen in earlier studies examining SNPs
in relation to cancer via distinct regulatory mechanisms (Jin
and Lee, 2013). Clearly, the contribution of SNPs in miRNA to
pharmacogenetic in general requires in-depth investigations.
Genetic association studies have supported specific SNPs in
ErbB genes to impact on ErbB biological activity and hence may
represent potential markers for understanding individual suscep-
tibility to anti-ErbB therapeutics. Below we are discussing the
status of SNPs challenges to exploit these for optimization of the
efficacy of anti-ErbB targeted therapeutics.
EGFR
Several polymorphic variations in the promoter region of EGFR
have been reported to impact on gene expression and function
(Figure 1, Supplemental Table 1). The CA-simple sequence repeat
1 (CA-SSR1) is a highly polymorphic locus (14–21 CA dinu-
cleotide repeats) situated in the first intron of EGFR. A lower CA-
CSSR1 repeat number was found tomodulate EGFR transcription
in vivo and in vitro and correlated with increased transcription
and protein expression (Gebhardt et al., 1999). The allele size dis-
tribution of CA-SSR1 demonstrates ethnic differences with East
Asian having longer allele than individuals of European descent
or African-Americans (Liu et al., 2011).Conversely, low CA-SSR1
number was associated with increased breast cancer risk in young
women (Brandt et al., 2004), while a high CA-SSR1 number
was correlated with better prognosis in luminal A breast cancer
(Leite et al., 2014). Studies analyzing Asian population showed
that the low CA repeat polymorphism is associated with better
drug response and prolonged survival (Ichihara et al., 2007; Han
et al., 2014). A second key polymorphism within EGFR path-
ways (R521K, previously assigned as R497K, rs2227983) is a single
nucleotide change (G–A) in the codon 497 of the EGFR (Figure 1)
leading to an arginine-lysine substitution in the extracellular
domain of the subdomain IV. This variant is thought to decrease
the ligand binding affinity of the receptor, thus dampening down-
stream impact of activation of downstream target such a CMYC
andVEGF (Wang et al., 2007; Hsieh et al., 2012). R521K polymor-
phism has been associated with good prognostic features in breast
cancer especially in patients with luminal A subtypes, as well as
non-small cell lung, colorectal, and head and neck cancers (Wang
et al., 2007; Sasaki et al., 2009; Hsieh et al., 2012; Leite et al., 2014).
Other studies have reported that R521K polymorphism is associ-
ated with favorable outcome in cetuximab-based and 5-FU-based
chemotherapy but shows negative correlation in gefitinib-based
chemotherapy (Wang et al., 2007; Lurje et al., 2008; Sasaki et al.,
2009; Dahan et al., 2011; Hsieh et al., 2012; Leite et al., 2014).
This indicate that SNP in individual gene, whether it would affect
cancer cell proliferation or not, may influence the chromosome
instability (CIN) and even that cancer progression is not altered
remarkably it can result different profiles of clinical response to
chemotherapy; however, further investigation still is necessary
and the field is very promising.
Recent genome-wide studies (GWAS) have identified an EGFR
polymorphisms (rs2252586 and rs11979158) to be associated
with increased glioma risk (Sanson et al., 2011). Two further
polymorphisms in the promoter region of EGFR, SNPs -216
(rs712829) and -191 (rs712830), were associated with increased
protein synthesis; these SNPs are rare in East Asian populations
compared to other ethnicities (Liu et al., 2011). SNPs -216 vari-
ant is located -216 upstream from the initiator ATG and the
change of nucleoside is guanine to thymine (G/T or T/T) in a
important binding site for the transcription factor SP1 that is nec-
essary for activation of EGFR promoter activity (Liu et al., 2005).
This variant is frequent in individuals of European descent and
African-American than Asians (Liu et al., 2005) and has been
associated with increased intrinsic gene expression (Liu et al.,
2011). Furthermore, patients harboring SNP-216 and CA-SSR1
germline polymorphisms were more likely to present somatic
mutations of EGFR, in particular microdeletions of exon 19.
These deletions are common in lung cancer and were reported
to strongly predict response to TKI (Liu et al., 2011).
Besides polymorphic variations, somatic mutations identified
in ErbB genes, including EGFR (Figures 1, 2) greatly influence
in the receptor activity and interaction with TKIs, it is of funda-
mental importance to investigate the cooperation between SNPs
and cancer-associated somatic mutations in ErbB genes to bet-
ter understand the utility of ErbB polymorphisms to predict
individual susceptibility to anti-ErbB therapeutics.
ERBB2
The most investigated ERBB2 polymorphism related to can-
cer risk is I655V (rs1136201) located at the codon 655
(ATC/isoleucine to GTC/valine) in the transmembrane domain
of the receptor (Figure 1, Supplemental Table 2) (Kuraoka et al.,
2003; Puputti et al., 2006; Han et al., 2014). The amino acid
change could result in increased protein tyrosine kinase activ-
ity. Tumors harboring the I655V polymorphism showed higher
tumorigenic potential in preclinical models and breast cancers
expressing this variant also manifest an aggressive phenotype
(Han et al., 2014). I655Vpolymorphism confers a higher risk of
trastuzumab-associated cardiotoxicity but does not directly affect
patients’ survival, and hence it may be useful for the prevention of
cardiovascular events in patient receiving after therapy (Beauclair
et al., 2007). Further, a systematic review andmeta-analysis study-
ing ErbB2 polymorphism in over 45,000 breast cancer patients
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FIGURE 2 | Distribution of the relative percentage of somatic mutations
among different cancers types according to the cataloge of somatic
mutations in cancer (COSMIC) database in human primary tumors. Each
panel shows mutations rates for corresponding ErbB (A. EGFR; B. ErbB2; C.
ErbB3; D. ErbbB4) per tumor tissue affected (http://cancer.sanger.ac.uk/
showed that there is a lack of experiments replication for associa-
tion studies between the polymorphic variants and cancer risk, as
well as lack of quality control of genotyping assays or publication
bias influencing the results (Dahabreh and Murray, 2011).
ERBB3
Compared to the other members of the ErbB family, ErbB3 recep-
tor has been under-investigated in part because it was initially
identified as an inactive kinase receptor whose function depends
on interaction with ErbB partners, primarily through het-
erodimerization. Therefore, functional polymorphisms in ERBB3
were long neglected for this pseudo-kinase (Shi et al., 2010).
Recent studies revealed at least 1091 polymorphic forms in
human ERBB3 gene (dbSNP database; http://www.ncbi.nlm.nih.
gov/snp) (Figure 1, Supplemental Table 3). However, only one
study reported clinical relevance of the polymorphism 276C/T
(rs2271188) in the promoter region of the ERBB3. This variant
affected gene expression contributing to genetic susceptibility and
was associated with higher risk of lung cancer in never-smokers
(Sung et al., 2012). Noticeable, one research group reported the
association of ErbB3 overexpression with resistance to tamox-
ifen as well as to small molecule TKI in breast cancer; however, a
possible contribution of SNPs was not addressed (Liu et al., 2007).
ERBB4
Multiple SNPs in the ERBB4 promoter region were associated
with adverse clinical features (Figure 1, Supplemental Table 4).
The frequency and prognostic significance of two ERBB4 pro-
moter region variants, -782G/T (rs62626348) and -815A/T
(rs62626347), were investigated in a large cohort of breast can-
cer patients. 782G/T conferred highest cancer risk (Rokavec et al.,
2007) but another study observed an association of this variant
with well-differentiated breast tumor (Kurppa et al., 2014). The
variant815A/T was correlated with poor survival and proposed
as a prognostic marker in high-risk early breast cancer (Kurppa
et al., 2014). A genome-wide association study (GWAS) identified
a breast cancer risk variant in ERBB4 at 2q34 (rs13393577) to
occur in European and Chinese populations. However, the impact
of ErbB4 polymorphisms on response to anti-ErbB therapeutics
remains to be established.
CONCLUSION AND PERSPECTIVES
Anti-ErbB drugs are becoming cornerstone therapeutics for many
cancers and in particular for lung and breast cancers subtype
where combination of anti-ErbB with conventional chemother-
apy has drastically changed the patient’s outcome. Yet a dilemma
for the oncologist is how to predict with certainty patients likely
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will respond to primary treatment from those that may be intrin-
sically resistant despite the presence of the ErbB target. With the
advent of the genome-wide scanning technologies, remarkable
advances have been made in the identification of single polymor-
phic variants in ErbB genes. However, the significance of most
SNPs leading to amino acid substitutions to ErbB receptor sig-
naling and cell susceptibility to anti-ErbB therapeutics remains to
be established. With the availability of technologies to manipu-
late gene expression in intact cells, such as the clustered regularly
interspaced short palindromic repeat (CRISPER) system, allow
to develop cell models expressing wild-type versus polymorphic
variants for functional studies, which are essential for surveying
the implications of ErbB SNPs landscape in greater details, in
particular in relation to receptor activity, receptor topology, and
response to anti-ErbB therapeutics. This represents the backbone
to draw testable hypotheses on SNP-impacts on receptor structure
activity and interaction with the inhibitor. This knowledge can be
later exploited for the design of more meaningful large-scale SNP
association studies. In this respect, among challenging questions
is that relevant SNPs may likely produce borderline resistance
or sensitivity to anti-ErbB, which is difficult to investigate in
the clinical setting. Alternatives for standard clinical trials such
as clinical trial simulations may be required to fill this gap and
ultimately design alternative molecules that target relevant SNP
genetic variants.In summary, identification of ErbB genetic vari-
ations that can predict drug response or resistance is a first step
toward exploiting the utility of pharmacogenetics to tailor indi-
vidual ErbB-based therapy regimens, a prerequisite to optimize
care cancer.
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